About: Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study
Creator	Wang, Jian Hong, Wenxin Deng, Ying Zhang, Yuying He, Xi Chan, Juliana Li, Ka Zeng, Chen, Xudan Shing, Baoyi, Zhu Chen, Jingfeng Qiu, Shuang Zheng, Haipeng
Source	MedRxiv
abstract	Background: The novel coronavirus disease 2019 (COVID-19) characterized by respiratory symptoms has become a global pandemic although factors influencing viral RNA clearance remained unclear to inform optimal isolation period and treatment strategies. Methods: In this retrospective study, we included patients with confirmed COVID-19 admitted to Guangzhou Eighth People's Hospital from 20th January 2020 to 15th March 2020. The associations of clinical characteristics and treatment regimens on time to viral RNA clearance were analyzed. Results: We examined 284 consecutive COVID-19 cases, accounting for 82% of confirmed cases in Guangzhou during this period. At the time of reporting (20th March 2020), 276 (97.2%) had recovered and were discharged from hospital with a median hospital stay of 18 days (interquartile range [IQR]:13-24). Overall, 280 patients achieved viral RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. Amongst them, 66.1% had viral RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness onset to hospital admission, high body temperature, and corticosteroid use were associated with delayed clearance of viral RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved viral RNA clearance. The use of lopinavir/ritonavir was associated with delayed clearance of viral RNA even after adjusting for confounders. Conclusion: In patients with COVID-19, isolation for a minimum of 21 days after onset of illness may be warranted, while the use of antiviral drugs does not enhance viral RNA clearance.
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.1101/2020.04.09.20058941
has license	medrxiv
sha1sum (hex)	cbd35758e3c682c496db060580928217f156b3a2
schema:url	https://doi.org/10.1101/2020.04.09.20058941
resource representing a document's title	Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study
resource representing a document's body	covid:cbd35758e3c682c496db060580928217f156b3a2#body_text
is schema:about of	named entity 'preprint' named entity 'viral RNA' named entity 'China' named entity 'preprint' named entity 'corticosteroid' named entity 'viral RNA' named entity 'oseltamivir' named entity 'cardiovascular diseases' named entity 'corticosteroid' named entity 'oseltamivir' named entity 'malignancy' named entity 'cough' named entity 'Guangzhou' named entity 'preprint' named entity 'Guangzhou' named entity 'pneumonia' named entity 'medRxiv' named entity 'preprint' named entity 'comorbid' named entity 'D-dimer' named entity 'lopinavir/ritonavir' named entity 'peer-reviewed' named entity 'fixed dose combination' named entity 'supportive treatment' named entity 'clinical trial' named entity 'arbidol' named entity 'corticosteroid' named entity 'COVID-19' named entity 'preprint' named entity 'COVID' named entity 'medRxiv' named entity 'medRxiv' named entity 'smokers' named entity 'chest CT' named entity 'viral RNA' named entity 'viral RNA' named entity 'empirical treatment' named entity 'preprint' named entity 'preprint' named entity 'ritonavir' named entity 'viral RNA' named entity 'COVID-19' named entity 'RT-PCR test' named entity 'sample size' named entity 'RT-PCR test' named entity 'incubation period' named entity 'COVID' named entity 'asymptomatic' named entity 'viral RNA' named entity 'corticosteroid' named entity 'preprint' named entity 'antiviral drugs' named entity 'viral RNA' named entity 'antiviral drugs' named entity 'monotherapy' named entity 'antiviral drugs' named entity 'preprint' named entity 'serum albumin' named entity 'preprint' named entity 'rank variable' named entity 'antiviral drug' named entity 'medRxiv' named entity 'corticosteroid' named entity 'preprint' named entity 'antiviral drugs' named entity 'influenza' named entity 'interquartile range' named entity 'oxygen therapy' named entity 'COVID-19' named entity 'asymptomatic patients' named entity 'Guangzhou' named entity 'clearance rate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software